Trial · NCT01121575
Results by group357
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 357
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Overview of Treatment-emergent All Causalities Adverse Events (AEs) in Escalation Phase | Crizotinib 200 mg BID/ Dacomitinib 30 mg QD | Participants with AEs | 14 | participants | |
| Overview of Treatment-emergent All Causalities Adverse Events (AEs) in Escalation Phase | Crizotinib 200 mg BID/ Dacomitinib 45 mg QD | Participants with AEs | 6 | participants | |
| Overview of Treatment-emergent All Causalities Adverse Events (AEs) in Escalation Phase | Crizotinib 250 mg BID/ Dacomitinib 30 mg QD | Participants with AEs | 7 | participants | |
| Overview of Treatment-emergent All Causalities Adverse Events (AEs) in Escalation Phase | Crizotinib 250 mg QD/ Dacomitinib 45 mg QD | Participants with AEs | 6 | participants | |
| Overview of Treatment-emergent All Causalities Adverse Events (AEs) in Escalation Phase | Crizotinib 200 mg BID/ Dacomitinib 30 mg QD | Participants with Grade 3 or 4 AEs | 9 | participants | |
| Overview of Treatment-emergent All Causalities Adverse Events (AEs) in Escalation Phase | Crizotinib 200 mg BID/ Dacomitinib 45 mg QD | Participants with Grade 3 or 4 AEs | 4 | participants | |
| Overview of Treatment-emergent All Causalities Adverse Events (AEs) in Escalation Phase | Crizotinib 250 mg BID/ Dacomitinib 30 mg QD | Participants with Grade 3 or 4 AEs | 5 | participants | |
| Overview of Treatment-emergent All Causalities Adverse Events (AEs) in Escalation Phase | Crizotinib 250 mg QD/ Dacomitinib 45 mg QD | Participants with Grade 3 or 4 AEs | 5 | participants | |
| Overview of Treatment-emergent All Causalities Adverse Events (AEs) in Escalation Phase | Crizotinib 200 mg BID/ Dacomitinib 30 mg QD | Participants with Grade 5 AEs | 3 | participants | |
| Overview of Treatment-emergent All Causalities Adverse Events (AEs) in Escalation Phase | Crizotinib 200 mg BID/ Dacomitinib 45 mg QD | Participants with Grade 5 AEs | 0 | participants | |
| Overview of Treatment-emergent All Causalities Adverse Events (AEs) in Escalation Phase | Crizotinib 250 mg BID/ Dacomitinib 30 mg QD | Participants with Grade 5 AEs | 0 | participants | |
| Overview of Treatment-emergent All Causalities Adverse Events (AEs) in Escalation Phase | Crizotinib 250 mg QD/ Dacomitinib 45 mg QD | Participants with Grade 5 AEs | 1 | participants | |
| Overview of Treatment-emergent All Causalities Adverse Events (AEs) in Escalation Phase | Crizotinib 200 mg BID/ Dacomitinib 30 mg QD | Participants with SAEs | 6 | participants | |
| Overview of Treatment-emergent All Causalities Adverse Events (AEs) in Escalation Phase | Crizotinib 200 mg BID/ Dacomitinib 45 mg QD | Participants with SAEs | 2 | participants | |
| Overview of Treatment-emergent All Causalities Adverse Events (AEs) in Escalation Phase | Crizotinib 250 mg BID/ Dacomitinib 30 mg QD | Participants with SAEs | 1 | participants | |
| Overview of Treatment-emergent All Causalities Adverse Events (AEs) in Escalation Phase | Crizotinib 250 mg QD/ Dacomitinib 45 mg QD | Participants with SAEs | 4 | participants | |
| Overview of Treatment-emergent All Causalities AEs in Expansion Phase | Expansion Cohort 1 | Participants with AEs | 22 | Participants | |
| Overview of Treatment-emergent All Causalities AEs in Expansion Phase | Expansion Cohort 2 | Participants with AEs | 11 | Participants | |
| Overview of Treatment-emergent All Causalities AEs in Expansion Phase | Expansion Cohort 1 | Participants with Grade 3 or 4 AEs | 12 | Participants | |
| Overview of Treatment-emergent All Causalities AEs in Expansion Phase | Expansion Cohort 2 | Participants with Grade 3 or 4 AEs | 8 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01121575/results